

# Bettina E Hansen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1326109/publications.pdf>

Version: 2024-02-01

158  
papers

14,087  
citations

22132

59  
h-index

20943

115  
g-index

158  
all docs

158  
docs citations

158  
times ranked

12023  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. JAMA - Journal of the American Medical Association, 2012, 308, 2584.	3.8	1,327
2	Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet, The, 2005, 365, 123-129.	6.3	1,105
3	Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid. Gastroenterology, 2009, 136, 1281-1287.	0.6	387
4	Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon $\alpha$ -2b. Gastroenterology, 2008, 135, 459-467.	0.6	373
5	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology, 2014, 147, 1338-1349.e5.	0.6	365
6	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152, 1975-1984.e8.	0.6	355
7	Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa. Gastroenterology, 2009, 137, 2002-2009.	0.6	349
8	Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology, 2004, 39, 804-810.	3.6	321
9	Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology, 2004, 39, 500-508.	3.6	315
10	Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology, 2008, 47, 1856-1862.	3.6	262
11	Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology, 2010, 52, 1251-1257.	3.6	259
12	Comparison of echocardiographic methods with magnetic resonance imaging for assessment of right ventricular function in children. American Journal of Cardiology, 1995, 76, 589-594.	0.7	250
13	Treatment with Peg-Interferon alpha-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype. American Journal of Gastroenterology, 2006, 101, 297-303.	0.2	249
14	Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Journal of Hepatology, 1997, 26, 961-966.	1.8	219
15	External Validation of the Fatty Liver Index for Identifying Nonalcoholic Fatty Liver Disease in a Population-based Study. Clinical Gastroenterology and Hepatology, 2013, 11, 1201-1204.	2.4	218
16	Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology, 2010, 52, 454-461.	3.6	215
17	Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology, 2013, 58, 872-880.	3.6	201
18	Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: Results from the Rotterdam study. Journal of Hepatology, 2012, 57, 1305-1311.	1.8	198

#	ARTICLE	IF	CITATIONS
19	Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). <i>Gut</i> , 2014, 63, 292-299.	6.1	195
20	Nucleos(t)ide Analogues Only Induce Temporary Hepatitis B e Antigen Seroconversion in Most Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2010, 139, 491-498.	0.6	180
21	Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 498-510.	5.2	180
22	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. <i>Gut</i> , 2015, 64, 1289-1295.	6.1	178
23	Quantification of right ventricular function with magnetic resonance imaging in children with normal hearts and with congenital heart disease. <i>American Heart Journal</i> , 1995, 130, 828-837.	1.2	173
24	Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2012, 142, 513-520.e1.	0.6	171
25	A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. <i>Journal of Virological Methods</i> , 2003, 110, 201-209.	1.0	161
26	Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. <i>Gut</i> , 2013, 62, 760-765.	6.1	159
27	Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. <i>Journal of Hepatology</i> , 2012, 56, 1006-1011.	1.8	155
28	Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response. <i>Hepatology</i> , 2011, 54, 443-451.	3.6	150
29	Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials. <i>Gastroenterology</i> , 1999, 117, 408-413.	0.6	146
30	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 43, 250-257.	1.8	143
31	Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 Patients. <i>American Journal of Gastroenterology</i> , 2006, 101, 2044-2050.	0.2	143
32	Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. <i>Journal of Hepatology</i> , 2011, 54, 449-454.	1.8	134
33	Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus. <i>Gastroenterology</i> , 2010, 139, 1934-1941.	0.6	123
34	Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss. <i>Journal of Infectious Diseases</i> , 2011, 204, 415-418.	1.9	122
35	A randomized comparison of electrocautery incision with Savary bougienage for relief of anastomotic gastroesophageal strictures. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 849-855.	0.5	110
36	Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. <i>Hepatology</i> , 2007, 46, 388-394.	3.6	107

#	ARTICLE	IF	CITATIONS
37	Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 905-913.	5.2	106
38	The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: Results of a double-blind, randomized, placebo-controlled trial. <i>Hepatology</i> , 2010, 52, 1334-1340.	3.6	104
39	Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2010, 52, 493-500.	1.8	103
40	Prior radiation and/or chemotherapy has no effect on the outcome of metal stent placement for oesophagogastric carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 163-170.	0.8	98
41	Metastases in Supraclavicular Lymph Nodes in Lung Cancer: Assessment with Palpation, US, and CT. <i>Radiology</i> , 2004, 232, 75-80.	3.6	97
42	Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals. <i>Gastroenterology</i> , 2018, 154, 515-517.e3.	0.6	96
43	A Randomized Trial of Peginterferon $\alpha$ -2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2010, 105, 1762-1769.	0.2	83
44	Serum liver enzymes are associated with all-cause mortality in an elderly population. <i>Liver International</i> , 2014, 34, 296-304.	1.9	83
45	Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. <i>Journal of Hepatology</i> , 1999, 30, 192-198.	1.8	80
46	Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trial. <i>Journal of Hepatology</i> , 2006, 45, 539-546.	1.8	76
47	Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 36, 641-647.	1.9	76
48	Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 649-657.	3.7	76
49	Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2012, 56, 67-75.	3.6	75
50	Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2002, 37, 137-144.	1.8	70
51	Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. <i>Journal of Hepatology</i> , 2010, 53, 468-476.	1.8	68
52	Hepatitis B Surface Antigen Declines and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV. <i>Journal of Infectious Diseases</i> , 2012, 206, 974-980.	1.9	68
53	Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. <i>Liver International</i> , 2012, 32, 622-628.	1.9	68
54	Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. <i>Journal of Hepatology</i> , 2019, 70, 666-673.	1.8	66

#	ARTICLE	IF	CITATIONS
55	Increased incidence of early <i>de novo</i> cancer in liver graft recipients treated with cyclosporine: An association with C<sub>2</sub> monitoring and recipient age. Liver Transplantation, 2010, 16, 837-846.	1.3	65
56	Histological features in western patients with idiopathic non-�cirrhotic portal hypertension. Histopathology, 2013, 62, 1083-1091.	1.6	65
57	Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 463-472.	2.4	64
58	Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response. Hepatology, 2006, 44, 721-727.	3.6	63
59	Durable Hepatitis B Surface Antigen Decline in Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon-�2B: Relation to Response and HBV Genotype. Antiviral Therapy, 2012, 17, 9-17.	0.6	63
60	Generic and disease-specific health related quality of life in non-cirrhotic, cirrhotic and transplanted liver patients: a cross-sectional study. BMC Gastroenterology, 2003, 3, 33.	0.8	62
61	A Prospective Open Study of the Efficacy of High-�Dose Recombinant Hepatitis B Rechallenge Vaccination in HIV-�Infected Patients. Journal of Infectious Diseases, 2008, 197, 292-294.	1.9	62
62	Volume Measurements of the Anal Sphincter Complex in Healthy Controls and Fecal-Incontinent Patients With a Three-Dimensional Reconstruction of Endoanal Ultrasonography Images. Diseases of the Colon and Rectum, 2005, 48, 540-548.	0.7	57
63	Endoscopic visible light spectroscopy: a new, minimally invasive technique to diagnose chronic GI ischemia. Gastrointestinal Endoscopy, 2011, 73, 291-298.	0.5	56
64	Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. BMC Gastroenterology, 2004, 4, 13.	0.8	54
65	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2076-2084.e2.	2.4	54
66	MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation. Journal of Hepatology, 2013, 59, 1231-1238.	1.8	52
67	The Liver Disease Symptom Index 2.0; Validation of a Disease-Specific Questionnaire. Quality of Life Research, 2004, 13, 1469-1481.	1.5	51
68	Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology, 2010, 52, 1225-1231.	3.6	50
69	US and Fluoroscopic-guided Percutaneous Jejunostomy: Experience in 49 Patients. Journal of Vascular and Interventional Radiology, 2000, 11, 101-106.	0.2	49
70	A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. Journal of Clinical Virology, 2011, 51, 175-178.	1.6	49
71	Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scandinavian Journal of Gastroenterology, 2011, 46, 962-972.	0.6	48
72	Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine, 2013, 31, 1040-1044.	1.7	48

#	ARTICLE	IF	CITATIONS
73	Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. <i>Gastrointestinal Endoscopy</i> , 2008, 67, 821-827.	0.5	46
74	Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. <i>Journal of Hepatology</i> , 2010, 53, 455-459.	1.8	46
75	Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. <i>Journal of Hepatology</i> , 2013, 58, 898-903.	1.8	46
76	Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1546-1557.	1.9	45
77	Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome. <i>Liver International</i> , 2008, 28, 249-256.	1.9	44
78	The cervical spine in rheumatoid arthritis: relationship between neurologic signs and morphology on MR imaging and radiographs. <i>Skeletal Radiology</i> , 1996, 25, 113-118.	1.2	43
79	Predictors of Treatment Failure for Hip and Knee Prosthetic Joint Infections in the Setting of 1- and 2-Stage Exchange Arthroplasty: A Multicenter Retrospective Cohort. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz452.	0.4	43
80	Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. <i>Journal of Hepatology</i> , 1998, 28, 951-959.	1.8	41
81	Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. <i>Journal of Hepatology</i> , 2004, 40, 689-695.	1.8	41
82	Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1999, 31, 256-262.	1.8	40
83	Immunoglobulin G4-related Prostatitis: A Case-control Study Focusing on Clinical and Pathologic Characteristics. <i>Urology</i> , 2014, 83, 521-527.	0.5	40
84	Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. <i>Journal of Hepatology</i> , 2014, 60, 191-196.	1.8	40
85	Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. <i>Journal of Medical Virology</i> , 2007, 79, 1055-1063.	2.5	39
86	Prediction of the response to peginterferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. <i>Journal of Medical Virology</i> , 2010, 82, 1135-1142.	2.5	39
87	Generic and disease-specific health related quality of life of liver patients with various aetiologies: A survey. <i>Quality of Life Research</i> , 2007, 16, 375-388.	1.5	37
88	Comparable Efficacy of Low- Versus High-Dose Induction Corticosteroid Treatment in Autoimmune Pancreatitis. <i>Pancreas</i> , 2014, 43, 261-267.	0.5	37
89	Is Textbook Outcome a valuable composite measure for short-term outcomes of gastrointestinal treatments in the Netherlands using hospital information system data? A retrospective cohort study. <i>BMJ Open</i> , 2018, 8, e019405.	0.8	37
90	Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 1087-1094.	0.6	36

#	ARTICLE	IF	CITATIONS
91	Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1.	0.8	36
92	Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1098-1105.e1.	2.4	35
93	Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. <i>BMC Gastroenterology</i> , 2010, 10, 144.	0.8	34
94	A Randomized Controlled Study of Accelerated Versus Standard Hepatitis B Vaccination in HIV-Positive Patients. <i>Journal of Infectious Diseases</i> , 2011, 203, 984-991.	1.9	34
95	Close Monitoring of Hepatitis B Surface Antigen Levels Helps Classify Flares During Peginterferon Therapy and Predicts Treatment Response. <i>Clinical Infectious Diseases</i> , 2013, 56, 100-105.	2.9	34
96	Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. <i>Journal of Hepatology</i> , 2001, 34, 435-440.	1.8	33
97	Viral dynamics in chronic hepatitis B patients during lamivudine therapy. <i>Liver</i> , 2002, 22, 121-126.	0.1	33
98	Paired, quantitative measurements of hepatitis B virus DNA in saliva, urine and serum of chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 1173-1179.	0.8	33
99	The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. <i>Journal of Hepatology</i> , 2002, 37, 253-258.	1.8	31
100	?-Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-?-2b in chronic hepatitis C non-responders. <i>Liver International</i> , 2007, 27, 070816165951003-???	1.9	30
101	Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. <i>BMC Gastroenterology</i> , 2012, 12, 11.	0.8	30
102	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , 2015, 64, 322-331.	6.1	30
103	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1688-1697.e14.	2.4	30
104	Update on PADI trial: Percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia. <i>Journal of Vascular Surgery</i> , 2009, 50, 687-689.	0.6	28
105	Serum Markers and Intestinal Mucosal Injury in Chronic Gastrointestinal Ischemia. <i>Digestive Diseases and Sciences</i> , 2011, 56, 506-512.	1.1	28
106	Successful Treatment with Peginterferon alfa-2b of HBeAg-positive HBV Non-Responders to Standard Interferon or Lamivudine. <i>American Journal of Gastroenterology</i> , 2006, 101, 2523-2529.	0.2	27
107	Early HBeAg Loss During Peginterferon $\alpha$ -2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients. <i>American Journal of Gastroenterology</i> , 2009, 104, 2449-2457.	0.2	27
108	Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 992-999.	1.8	25



#	ARTICLE	IF	CITATIONS
109	Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine+/-famciclovir or lamivudine+/-ganciclovir. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 1007-1011.	0.8	24
110	Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7. <i>Antiviral Therapy</i> , 2012, 17, 657-667.	0.6	24
111	Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma. <i>Journal of Human Genetics</i> , 2012, 57, 26-32.	1.1	24
112	Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis. <i>Liver International</i> , 2021, 41, 535-544.	1.9	23
113	Discriminant analysis using a multivariate linear mixed model with a normal mixture in the random effects distribution. <i>Statistics in Medicine</i> , 2010, 29, 3267-3283.	0.8	22
114	Use of Visible Light Spectroscopy to Diagnose Chronic Gastrointestinal Ischemia and Predict Response to Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 122-130.e1.	2.4	22
115	Primary Sclerosing Cholangitis in Children With Inflammatory Bowel Diseases Is Associated With Milder Clinical Activity But More Frequent Subclinical Inflammation and Growth Impairment. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1509-1517.e7.	2.4	22
116	Drug Therapies for Ulcerative Proctitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2157-2178.	0.9	21
117	Pretreatment Intrahepatic CD8+Cell Count Correlates with Virological Response to Antiviral Therapy in Chronic Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2003, 188, 1528-1532.	1.9	20
118	Integrity of the Anal Sphincters After Pouch-Anal Anastomosis: Evaluation With Three-Dimensional Endoanal Ultrasonography. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 1728-1735.	0.7	20
119	Neuroenteric peptides affect natural killer activity by intestinal lamina propria mononuclear cells. <i>Journal of Neuroimmunology</i> , 1993, 42, 139-145.	1.1	18
120	A Comparative Study of Diagnostic Scoring Systems for Autoimmune Pancreatitis. <i>Pancreas</i> , 2014, 43, 559-564.	0.5	18
121	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , 2014, 61, 482-491.	1.8	18
122	TNF- $\alpha$ gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 378-386.	0.6	17
123	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	2.4	17
124	Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]. <i>BMC Gastroenterology</i> , 2003, 3, 24.	0.8	16
125	Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants. <i>Antiviral Research</i> , 2013, 97, 312-317.	1.9	16
126	Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program. <i>Gastroenterology</i> , 2018, 155, 1392-1399.e5.	0.6	16



#	ARTICLE	IF	CITATIONS
127	Pegylated Interferon Results in Higher Serological, but Not Virological, Response Rates When Compared to Continuous Entecavir. <i>Antiviral Therapy</i> , 2012, 17, 1605-1608.	0.6	15
128	Heterotopic vs. orthotopic liver transplantation for chronic liver disease: A case-control comparison of short-term and long-term outcomes. <i>Liver Transplantation</i> , 2005, 11, 396-401.	1.3	14
129	Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1933-1940.e1.	2.4	14
130	Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores. <i>European Radiology</i> , 2022, 32, 67-77.	2.3	14
131	Renal Dysfunction After Liver Transplantation: Effect of Donor Type. <i>Liver Transplantation</i> , 2020, 26, 799-810.	1.3	13
132	Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1451-1458.e4.	2.4	12
133	The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. <i>Transplantation</i> , 2020, 104, 2087-2096.	0.5	12
134	Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon $\alpha$ -2a. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1012-1019.	0.8	11
135	Pediatric Wilson Disease Presenting as Acute Liver Failure. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 71, e90-e96.	0.9	11
136	Trends in indications and outcomes of liver transplantation in Canada: A multicenter retrospective study. <i>Transplant International</i> , 2021, 34, 1444-1454.	0.8	11
137	Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 427-435.	0.7	10
138	Risk stratification and prognostic modelling in primary biliary cholangitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 95-106.	1.0	10
139	Internal medicine hospitalisations and liver disease: a comparative disease burden analysis of a multicentre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 689-698.	1.9	8
140	Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2022, 227, 113-122.	1.9	8
141	Identification of prosthetic hip and knee joint infections using administrative databases—A validation study. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 325-330.	1.0	7
142	The Impact of Primary Liver Disease and Social Determinants in a Mixed Donor Liver Transplant Program: A Single-Center Analysis. <i>Liver Transplantation</i> , 2021, 27, 1733-1746.	1.3	7
143	Clinical outcome after cyclosporine dose reduction based on C2 levels in long-term liver transplant patients. <i>Clinical Transplantation</i> , 2005, 19, 537-542.	0.8	6
144	Predicting treatment outcome following 24 weeks peginterferon $\alpha$ -2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6. <i>Hepatology</i> , 2007, 45, 258-259.	3.6	6

#	ARTICLE	IF	CITATIONS
145	Incidence of Hepatitis C Virus Infections Among Users of Human Immunodeficiency Virus Pre-exposure Prophylaxis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 674-681.	2.4	6
146	Reproducible radiographs of acetabular prostheses. <i>Acta Orthopaedica</i> , 1994, 65, 258-262.	1.4	5
147	Long-term outcomes of laparoscopic liver resection for hepatocellular carcinoma: A propensity score matched analysis of a high-volume North American center. <i>Surgery</i> , 2022, 171, 982-991.	1.0	5
148	Beyond Biochemical Responses, Use of Histologic Staging to Predict Outcomes of Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1033-1035.	2.4	4
149	Continuous Interferon- $\beta$ 2B Infusion in Combination with Ribavirin for Chronic Hepatitis C in Treatment-Experienced Patients. <i>Antiviral Therapy</i> , 2012, 17, 509-517.	0.6	3
150	HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo. <i>Journal of Medical Virology</i> , 2011, 83, 1917-1923.	2.5	3
151	Sustained Virological Response to Treatment in Patients With Chronic Hepatitis C—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1457.	3.8	3
152	Psychological consequences of MRI-based screening among women with strong family histories of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 497-508.	1.1	3
153	HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 259-261.	2.4	2
154	Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon- $\alpha$ 2B/ribavirin combination therapy after 4 weeks of treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1.	0.8	2
155	Effect of blood group and HLA matching on pancreas graft survival with the use of UW solution. <i>Transplant International</i> , 1995, 8, 366-373.	0.8	2
156	High-dose (peg)interferon therapy in treatment-naïve, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2015, 47, 87-88.	0.4	1
157	Corrigendum to “Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B” [Hepatology 37 (2002) 137–144]. <i>Journal of Hepatology</i> , 2002, 37, 708.	1.8	0
158	Editorial: liver transplantation for primary biliary cholangitis—the need for timely and more effective treatments. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 473-474.	1.9	0